Matthew Ho

@pennmedicine Heme/Onc Fellow via @UCDmedicine; @thebianchilab; @mayoMN_imres

[Matthew Ho @MatthewHoMD]

@RahulBanerjeeMD @MSKCancerCenter https://t.co/lFTR2jbcUm

Dr Maus's group showed the same thing! Back to back papers from different groups.

Reminds me of the back to back 2014 Science papers demonstrating cereblon-dependent degradation of IKZF1/IKZF3 by lenalidomide.

[Ronak H. Mistry, DO @rmistry91]

#ICYMI: the long-awaited updated @ASH_hematology #ITP guidelines are here!

With so many new agents for managing ITP, I’m excited for these recs to better help our patients achieve durable platelet responses and improved QOL

Link: https://t.co/QY57AsYnBE

[Matthew Ho @MatthewHoMD]

@Dokutah_Vyew It is reasonable to check SPEP in refractory/breakthrough cases but the more common causes (HITT/VITT, autoimmune disease, APLS, malignancy, PNH, vascular abnormalities, DIC) should be considered

[Matthew Ho @MatthewHoMD]

@Dokutah_Vyew Quite the opposite actually!

MITT is the only antibody-mediated thrombotic syndrome currently for which there is direct evidence linking an M-protein to thrombosis and even MITT is rare.

[Matthew Ho @MatthewHoMD]

Read the full review @AjHematology : https://t.co/FV7FrtlUVS.

@ZanwarSaurabh, @myelomaMD, @VincentRK

[Matthew Ho @MatthewHoMD]

When is thrombosis merely coincidental with an M-protein, and in which thrombotic disorders is there evidence that the M-protein itself can be pathogenic?

In our new review https://t.co/FV7FrtlUVS, we propose a framework for Monoclonal Gammopathy of Thrombotic Significance.

[Matthew Ho @MatthewHoMD]

Answering that question will require a broader understanding of the relationship between monoclonal proteins and specific thrombotic syndromes, multidisciplinary consensus, and the development of clinically available assays that can directly establish M-protein pathogenicity